The development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has transformed the management of advanced non–small-cell lung cancer (NSCLC) bearing an activating EGFR mutation, offering improved survival and tolerability when compared with the use of up-front cytotoxic chemotherapy.^1-3 Although response rates reach as high as 80% to the third-generation EGFR TKI osimertinib,⁴ response durations are limited, and subsequent disease progression is near inevitable. This has led to evaluation of combination therapy strategies up front and at disease progression with the intent to offer improved outcomes.

中文翻译：

---

旧有的又是新的：重新审视EGFR突变型非小细胞肺癌的前期化学疗法。

表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）的发展已改变了具有激活EGFR突变的晚期非小细胞肺癌（NSCLC）的治疗方法，与使用up相比，其生存率和耐受性得到改善前细胞毒性化疗。^1-3尽管对第三代EGFR TKI奥西替尼的应答率高达80％，但^4种应答持续时间有限，随后的疾病进展几乎不可避免。这已经导致了在治疗前和疾病发展过程中对联合治疗策略的评估，目的是提供更好的结果。